{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:51:15Z","timestamp":1793962275119,"version":"4.8.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 107476"],"award-info":[{"award-number":["CA 107476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 168762"],"award-info":[{"award-number":["CA 168762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA 186781"],"award-info":[{"award-number":["CA 186781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables including age, performance status, comorbidities, and eligibility for stem cell transplantation. In addition, another key variable that affects treatment strategy is risk stratification of patients into standard and high-risk MM. High-risk MM is defined by the presence of t(4;14), t(14;16), t(14;20), gain 1q, del(17p), or p53 mutation. In this paper, we provide algorithms for the treatment of newly diagnosed and relapsed MM based on the best available evidence. We have relied on data from randomized controlled trials whenever possible, and when appropriate trials to guide therapy are not available, our recommendations reflect best practices based on non-randomized data, and expert opinion. Each algorithm has been designed to facilitate easy decision-making for practicing clinicians. In all patients, clinical trials should be considered first, prior to resorting to the standard of care algorithms we outline.<\/jats:p>","DOI":"10.1038\/s41408-020-00359-2","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:02:30Z","timestamp":1601298150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":333,"title":["Multiple myeloma current treatment algorithms"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"359_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548\u201367 (2020).","journal-title":"Am. J. Hematol."},{"key":"359_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"359_CR3","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"359_CR4","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"359_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"S Kumar","year":"2018","unstructured":"Kumar, S. & Rajkumar, S. V. The multiple myelomas\u2014current concepts in cytogenetic classification and therapy. Nat. Rev. Clin. Oncol. 15, 409\u201321 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"359_CR6","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass, J. et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 20, e302\u2013e312 (2019).","journal-title":"Lancet Oncol."},{"key":"359_CR7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"359_CR8","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez, J. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123, 3073\u20133079 (2014).","journal-title":"Blood"},{"key":"359_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone induction followed by lenalidomide and dexamethasone maintenance in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant: results of the Randomised Phase III SWOG Trial S0777. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"359_CR10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","volume":"126","author":"M Attal","year":"2015","unstructured":"Attal, M. et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial). Blood 126, 391 (2015).","journal-title":"Blood"},{"key":"359_CR11","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"359_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41571-019-0198-0","volume":"16","author":"P Kapoor","year":"2019","unstructured":"Kapoor, P. & Rajkumar, S. V. MAIA under the microscope\u2014bringing trial design into focus. Nat. Rev. Clin. Oncol. 16, 339\u201340 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"359_CR13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood 136, 936\u2013945 (2020).","journal-title":"Blood"},{"key":"359_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29\u201338 (2019).","journal-title":"Lancet"},{"key":"359_CR15","doi-asserted-by":"publisher","unstructured":"Kumar, S. K. et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomised, controlled trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(20)30452-6 (2020).","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"359_CR16","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMc1101834","volume":"364","author":"BL Burnette","year":"2011","unstructured":"Burnette, B. L., Leung, N. & Rajkumar, S. V. Renal improvement in myeloma with bortezomib plus plasma exchange. N. Engl. J. Med. 364, 2365\u20132366 (2011).","journal-title":"N. Engl. J. Med."},{"key":"359_CR17","unstructured":"Moreau, P. et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Proc. ASH Annual Meeting (2015)."},{"key":"359_CR18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie, B. et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 138, 176\u201385 (2007).","journal-title":"Br. J. Haematol."},{"key":"359_CR19","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 7, e370\u2013e380 (2020).","journal-title":"Lancet Haematol."},{"key":"359_CR20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos, M. V., Oriol, A. & Martinez-Lopez, J. Bortezomib\/melphalan\/prednisone (VMP) versus bortezomib\/thalidomide\/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib\/thalidomide (VT) versus bortezomib\/prednisone (VP): a randomised trial in elderly untreated patients with multiple myeloma older than 65 years. Lancet Oncol. 11, 934\u2013941 (2010).","journal-title":"Lancet Oncol."},{"key":"359_CR21","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28, 5101\u20135109 (2010).","journal-title":"J. Clin. Oncol."},{"key":"359_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431\u201340 (2011).","journal-title":"Lancet Oncol."},{"key":"359_CR23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"359_CR24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar, S. et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114, 1729\u20131735 (2009).","journal-title":"Blood"},{"key":"359_CR25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J. Clin. Oncol. 29, 986\u2013993 (2011).","journal-title":"J. Clin. Oncol."},{"key":"359_CR26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2011","unstructured":"Larocca, A. et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. Blood 119, 933\u2013939 (2011).","journal-title":"Blood"},{"key":"359_CR27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo, A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414\u2013423 (2008).","journal-title":"Leukemia"},{"key":"359_CR28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson, M. T. et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 20, 1760\u201372 (2019).","journal-title":"Lancet Oncol."},{"key":"359_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91\u201397 (1996).","journal-title":"N. Engl. J. Med."},{"key":"359_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child, J. A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875\u201383 (2003).","journal-title":"N. Engl. J. Med."},{"key":"359_CR31","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand, J. P. et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J. Clin. Oncol. 23, 9227\u201333 (2005).","journal-title":"J. Clin. Oncol."},{"key":"359_CR32","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie, B. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J. Clin. Oncol. 24, 929\u2013936 (2006).","journal-title":"J. Clin. Oncol."},{"key":"359_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N. Engl. J. Med. 371, 895\u2013905 (2014).","journal-title":"N. Engl. J. Med."},{"key":"359_CR34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay, F. et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 16, 1617\u20131629 (2015).","journal-title":"Lancet Oncol."},{"key":"359_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","volume":"130","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study. Blood 130, 397 (2017).","journal-title":"Blood"},{"key":"359_CR36","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"359_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4065\/83.10.1131","volume":"83","author":"MA Gertz","year":"2008","unstructured":"Gertz, M. A. et al. Autologous stem cell transplantation in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplantation, and impact of a multidisciplinary quality initiative. Mayo Clin. Proc. 83, 1131\u20131135 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"359_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","volume":"133","author":"SK Kumar","year":"2019","unstructured":"Kumar, S. K., Buadi, F. K. & Rajkumar, S. V. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood 133, 652\u2013659 (2019).","journal-title":"Blood"},{"key":"359_CR39","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand, J. P. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92, 3131\u20133136 (1998).","journal-title":"Blood"},{"key":"359_CR40","first-page":"685a","volume":"88","author":"T Facon","year":"1996","unstructured":"Facon, T. et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood 88, 685a (1996).","journal-title":"Blood"},{"key":"359_CR41","doi-asserted-by":"crossref","unstructured":"Stadtmauer, E. A. et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the blood and marrow transplant clinical trials network (BMT CTN 0702-StaMINA Trial). Blood 2016;128:LBA-1-LBA-1.","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1"},{"key":"359_CR42","first-page":"401","volume":"130","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02\/HO95 study. Blood 130, 401 (2017).","journal-title":"Blood"},{"key":"359_CR43","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo, M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 7, e456\u2013e468 (2020).","journal-title":"Lancet Haematol."},{"key":"359_CR44","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"359_CR45","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"key":"359_CR46","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"359_CR47","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo, A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366, 1759\u20131769 (2012).","journal-title":"N. Engl. J. Med."},{"key":"359_CR48","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N. Engl. J. Med."},{"key":"359_CR49","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka, A. K. et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28, 690\u2013693 (2014).","journal-title":"Leukemia"},{"key":"359_CR50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253\u2013264 (2019).","journal-title":"Lancet"},{"key":"359_CR51","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar, S. K. et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 79, 867\u2013874 (2004).","journal-title":"Mayo Clin. Proc."},{"key":"359_CR52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"359_CR53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"359_CR54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel, D. S. et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 36, 728\u2013734 (2018).","journal-title":"J. Clin. Oncol."},{"key":"359_CR55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"359_CR56","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"359_CR57","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"359_CR58","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"MDJF San-Miguel","year":"2014","unstructured":"San-Miguel, M. D. J. F., Hungria, V. T. M. & Yoon, M. D. S. Randomized phase 3 trial of the deacetylase inhibitor panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. Lancet Oncol. 15, 1195\u20131206 (2014).","journal-title":"Lancet Oncol."},{"key":"359_CR59","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel, J. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 1055\u20131066 (2013).","journal-title":"Lancet Oncol."},{"key":"359_CR60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"359_CR61","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 18, 1327\u20131337 (2017).","journal-title":"Lancet Oncol."},{"key":"359_CR62","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394, 2096\u20132107 (2019).","journal-title":"Lancet"},{"key":"359_CR63","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br. J. Haematol. 178, 896\u2013905 (2017).","journal-title":"Br. J. Haematol."},{"key":"359_CR64","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMe1609835","volume":"375","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. & Kyle, R. A. Progress in myeloma\u2014a monoclonal breakthrough. N. Engl. J. Med. 375, 1390\u20131392 (2016).","journal-title":"N. Engl. J. Med."},{"key":"359_CR65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari, A. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130, 974\u2013981 (2017).","journal-title":"Blood"},{"key":"359_CR66","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","volume":"32","author":"S Bringhen","year":"2018","unstructured":"Bringhen, S. et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study. Leukemia 32, 1803\u20131807 (2018).","journal-title":"Leukemia"},{"key":"359_CR67","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379, 1811\u20131822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"359_CR68","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00277-017-3065-z","volume":"96","author":"M Kropff","year":"2017","unstructured":"Kropff, M. et al. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann. Hematol. 96, 1857\u20131866 (2017).","journal-title":"Ann. Hematol."},{"key":"359_CR69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson, P. G. et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 20, 781\u2013794 (2019).","journal-title":"Lancet Oncol."},{"key":"359_CR70","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/leu.2008.99","volume":"22","author":"M Pineda-Roman","year":"2008","unstructured":"Pineda-Roman, M. et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22, 1419\u20131427 (2008).","journal-title":"Leukemia"},{"key":"359_CR71","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson, P. G. et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma. J. Clin. Oncol. 27, 5713\u20135719 (2009).","journal-title":"J. Clin. Oncol."},{"key":"359_CR72","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson, P. G. et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123, 1826\u20131832 (2014).","journal-title":"Blood"},{"key":"359_CR73","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel, D. S. et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2817\u20132825 (2012).","journal-title":"Blood"},{"key":"359_CR74","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3324\/haematol.2018.208272","volume":"104","author":"S Bringhen","year":"2019","unstructured":"Bringhen, S. et al. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I\/II studies. Haematologica 104, 1640\u20131647 (2019).","journal-title":"Haematologica"},{"key":"359_CR75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"359_CR76","doi-asserted-by":"crossref","unstructured":"Dimopoulos M. A., et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. Proc. ASCO Annual Meeting Abstracts, A8501(2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.8501"},{"key":"359_CR77","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/bjh.14481","volume":"176","author":"UJ Mey","year":"2017","unstructured":"Mey, U. J. et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br. J. Haematol. 176, 770\u201382 (2017).","journal-title":"Br. J. Haematol."},{"key":"359_CR78","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.3324\/haematol.2014.110890","volume":"100","author":"P Rodon","year":"2015","unstructured":"Rodon, P. et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica 100, e56\u2013e59 (2015).","journal-title":"Haematologica"},{"key":"359_CR79","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach, J. et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30, 1005\u20131017 (2016).","journal-title":"Leukemia"},{"key":"359_CR80","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"359_CR81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(19)31711-8","volume":"394","author":"S Kumar","year":"2019","unstructured":"Kumar, S. & Rajkumar, S. V. Surrogate endpoints in randomised controlled trials: a reality check. Lancet 394, 281\u2013283 (2019).","journal-title":"Lancet"},{"key":"359_CR82","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24244","volume":"91","author":"AM Rajan","year":"2016","unstructured":"Rajan, A. M., Buadi, F. K. & Rajkumar, V. Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: case report and interesting observations. Am. J. Hematol. 91, E5\u2013E6 (2016).","journal-title":"Am. J. Hematol."},{"key":"359_CR83","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"359_CR84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"359_CR85","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp, M. S. et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J. Clin. Oncol. 38, 775\u2013783 (2020).","journal-title":"J. Clin. Oncol."},{"key":"359_CR86","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.20.00223","volume":"38","author":"S Kumar","year":"2020","unstructured":"Kumar, S. & Rajkumar, S. V. BiTEing the tumor. J. Clin. Oncol. 38, 2077\u20132079 (2020).","journal-title":"J. Clin. Oncol."},{"key":"359_CR87","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund, C. C. et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34, 1197\u20131201 (2020).","journal-title":"Leukemia"},{"key":"359_CR88","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"359_CR89","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069\u20133075 (2015).","journal-title":"Blood"},{"key":"359_CR90","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"359_CR91","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738\u20131744 (2013).","journal-title":"Leukemia"},{"key":"359_CR92","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","volume":"31","author":"K Neben","year":"2013","unstructured":"Neben, K. et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31, 4325\u20134332 (2013).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"359_CR93","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi, P. et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 6, e454 (2016).","journal-title":"Blood Cancer J."},{"key":"359_CR94","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"M-V Mateos","year":"2013","unstructured":"Mateos, M.-V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"359_CR95","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"359_CR96","doi-asserted-by":"publisher","unstructured":"Lonial, S., Dhodapkar, M. V., Rajkumar, S. V. Smoldering myeloma and the art of war. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.20.00875 (2020).","DOI":"10.1200\/JCO.20.00875"},{"key":"359_CR97","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","volume":"52","author":"G D\u2019Arena","year":"2011","unstructured":"D\u2019Arena, G. et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk. Lymphoma 52, 771\u2013775 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"359_CR98","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","volume":"113","author":"P Musto","year":"2008","unstructured":"Musto, P. et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 113, 1588\u20131595 (2008).","journal-title":"Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00359-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:35:10Z","timestamp":1670232910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":98,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00359-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. reports consultancy (BMS\/Celgene, Takeda, and Janssen), and research funding (BMS\/Celgene, Takeda, Novartis, AbbVie, Janssen, and Amgen). The other author declares that he has no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"94"}}